Clinical Monograph: Alprazolam 2 mg (Blue Scored Bars)

B 7 0 7 blue 2 mg alprazolam bars. Source: Still Detox

1. Classification and Identification

Alprazolam is a short-acting, high-potency triazolo-analogue of the 1,4-benzodiazepine class. Chemically designated as 8-chloro-1-methyl-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine, its central structure incorporates a fused triazole ring that increases receptor binding affinity compared to classical benzodiazepines. Under the Anatomical Therapeutic Chemical (ATC) system, alprazolam is indexed under N05BA12.

• Physical Characteristics: Light blue, multi-scored rectangular bar featuring three debossed scores dividing the tablet into four 0.5 mg segments, imprinted with B 7 0 7 on one face.

• Controlled Status: Classified as a Controlled Substance (Schedule IV under the US CSA; Schedule 4 / Prescription Only Medicine internationally) due to rapid onset, high physical dependence liability, and significant illicit market demand.

2. Mechanism of Action and Pharmacodynamics

Alprazolam acts as a positive allosteric modulator at central FRENTEA​ receptor complexes:

• High-Affinity Receptor Modulation: Selectively binds to benzodiazepine site interfaces (α1​, α2​, α3​, or α5​ subunits paired with γ2​) on postsynaptic ionotropic FRENTEA​ receptors.

• Chloride Conductance Enhancement: Facilitates GABA-mediated opening of chloride channels, generating inward chloride currents that hyperpolarize neuronal membranes and suppress electrical excitability across the limbic system, thalamus, and cortex.

• Rapid Anxiolysis: High lipophilicity produces rapid central brain penetration, providing swift attenuation of acute panic attacks and autonomic hyperarousal.

3. Approved Clinical Indications and Dosing Scope

Licensing for 2 mg alprazolam formulations includes:

• Panic Disorder: Treatment of panic disorder with or without agoraphobia.

• Generalized Anxiety Disorder (GAD): Short-term management of severe acute anxiety states.

Dosing & Administration Regimen:

• High Unit Strength: The 2 mg “bar” represents the maximum immediate-release single-unit strength. It is typically reserved for established patients who have titrated up to high maintenance doses.

• Tablet Fractionation: The multi-scored design permits breaking into 0.5 mg, 1 mg, or 1.5 mg increments to facilitate precise dose titration and gradual tapering.

• Duration Restrictions: Use should be restricted to the shortest effective period (typically 2 to 4 weeks) with mandatory dose tapering upon discontinuation.

4. Pharmacokinetic Profile and Metabolic Fate

• Absorption: Rapidly and completely absorbed following oral administration. Peak plasma concentrations (Cmax​) occur within 1 to 2 hours (Tmax​).

• Distribution: Plasma protein binding is approximately 80% (primarily to serum albumin). Crosses the blood-brain barrier rapidly and distributes into placental tissue and breast milk.

• Biotransformation: Extensively metabolized in the liver via hepatic Cytochrome P450 enzymes (predominantly CYP3A4):

  • Hydroxylated to $\alpha$-hydroxyalprazolam (retains ~66% of parent potency) and 4-hydroxyalprazolam.

  • Metabolites are subsequently conjugated via glucuronidation prior to renal excretion.

• Elimination: Excreted primarily in urine as glucuronide conjugates and unchanged drug (~20%). Mean elimination half-life (t1/2​) ranges from 11 to 16 hours.

5. Physiological Effects and Adverse Event Spectrum

Alprazolam suppresses central nervous system arousal, motor control, and cognitive consolidation.

Adverse Drug Reaction Spectrum

• Very Common ($\ge 1/10$): Sedation, somnolence, fatigue, impaired coordination, ataxia, memory impairment, speech dysfluency.

• Common ($\ge 1/100$ to $<1/10$): Lightheadedness, cognitive dysfunction, irritability, constipation, dry mouth, changes in weight/appetite, blurred vision.

• Uncommon ($\ge 1/1,000$ to $<1/100$): Paradoxical disinhibition, rage, hallucinations, muscle weakness, confusion, altered libido.

• Rare / Severe (<1/1,000): Respiratory depression, severe withdrawal syndrome/seizures, hepatic failure, Stevens-Johnson syndrome.

6. Contraindications, Drug Interactions, and Clinical Precautions

Contraindicaciones

• Known hypersensitivity to alprazolam or other benzodiazepines.

• Concomitant use with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole).

• Severe acute respiratory insufficiency, sleep apnea, or myasthenia gravis.

• Acute narrow-angle glaucoma.

Key Drug Interactions

• Strong CYP3A4 Inhibitors (e.g., Ketoconazole, Itraconazole, Clarithromycin, Ritonavir): Significantly inhibit alprazolam metabolism, escalating plasma levels up to several-fold and provoking severe toxicity or prolonged sedation.

• Opioids, Alcohol, & CNS Depressants: Co-administration causes synergistic central nervous system and respiratory depression, dramatically increasing the risk of fatal overdose.

• CYP3A4 Inducers (e.g., Carbamazepine, St. John’s Wort, Rifampicin): Accelerate clearance, markedly reducing therapeutic plasma levels.

Clinical Precautions and Monitoring

• Counterfeit & Fentanyl Contamination Risk: Unofficial “blue bars” obtained outside licensed pharmacies carry an extreme risk of contamination with illicit fentanyl, novel designer benzodiazepines (e.g., bromazolam), or nitazenes, leading to fatal overdoses.

• Boxed Warning (Concomitant Opioid Use & Addiction/Dependence): Combined use with opioids increases risk of severe respiratory depression, coma, and death. Rapid withdrawal following continuous exposure causes life-threatening grand mal seizures and delirium tremens.

• High Abuse Liability: Alprazolam has higher reinforcement density and abuse potential than many other benzodiazepines due to its rapid absorption rate and high receptor affinity.